The results also provide the first evidence that HMMR facilitates metastasis through the JNK signaling pathway by interacting with MAP4K4, suggesting that this interaction could be a promising target for NSCLC treatment. This evidence concerns the gene MAP4K4 and non-small cell lung carcinoma.